title: Targeting and utilizing primary tumors as live vaccines: changing strategies.
abstract: Tumor metastases and relapse are the major causes of morbidity and mortality in cancer. Although surgery, chemotherapy and/or radiation therapy can typically control primary tumor growth, metastatic and relapsing tumors are often inaccessible or resistant to these treatments. An adaptive immune response can be generated during these conventional treatments of the primary tumor, and presumably both the primary tumor and secondary metastases share many of the same or similar antigenic characteristics recognized by the immune system. Thus, when established, this response should be able to control metastatic growth and tumor relapse. This review summarizes the mechanisms by which antitumor immune responses are generated, and recent findings supporting the hypothesis that many therapies targeting primary tumors can generate antitumor adaptive immune responses to prevent metastases and tumor relapse.
authors.affiliation: Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA. xyang2@bsd.uchicago.edu
authors.forename: Xuanming
authors.initials: X
authors.lastname: Yang
authors.forename: Eric D
authors.initials: ED
authors.lastname: Mortenson
authors.forename: Yang-Xin
authors.initials: YX
authors.lastname: Fu
mesh_terms: D056704:Adaptive Immunity; D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines
references.citation: Nat Med. 2004 Sep;10(9):909-15
references.pmid: 15340416
references.citation: Immunol Res. 1999;19(2-3):119-25
references.pmid: 10493167
references.citation: Cancer Res. 2011 Apr 1;71(7):2488-96
references.pmid: 21300764
references.citation: Nat Rev Immunol. 2006 Mar;6(3):205-17
references.pmid: 16498451
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613
references.citation: Annu Rev Immunol. 2009;27:83-117
references.pmid: 19007331
references.citation: Cancer Cell. 2011 Jan 18;19(1):101-13
references.pmid: 21251615
references.citation: J Exp Med. 2006 May 15;203(5):1259-71
references.pmid: 16636135
references.citation: Immunity. 2006 Sep;25(3):499-509
references.pmid: 16934497
references.citation: Nat Rev Immunol. 2008 Jan;8(1):59-73
references.pmid: 18097448
references.citation: J Immunol. 2007 Aug 1;179(3):1960-8
references.pmid: 17641063
references.citation: Blood. 2005 Sep 15;106(6):2018-25
references.pmid: 15914560
references.citation: Eur J Immunol. 2002 Jul;32(7):1969-79
references.pmid: 12115617
references.citation: Nat Med. 2007 Jan;13(1):54-61
references.pmid: 17187072
references.citation: Nat Med. 2000 Mar;6(3):283-9
references.pmid: 10700230
references.citation: Nat Med. 2000 Apr;6(4):443-6
references.pmid: 10742152
references.citation: Science. 2002 Oct 25;298(5594):850-4
references.pmid: 12242449
references.citation: Immunity. 2001 Feb;14(2):111-21
references.pmid: 11239444
references.citation: J Clin Invest. 2001 Dec;108(12):1771-80
references.pmid: 11748260
references.citation: Cancer Invest. 2003;21(6):873-86
references.pmid: 14735692
references.citation: J Clin Invest. 1998 Sep 15;102(6):1142-51
references.pmid: 9739048
references.citation: J Immunol. 1998 Dec 15;161(12):6853-60
references.pmid: 9862717
references.citation: Cancer Res. 2010 Jun 15;70(12):4850-8
references.pmid: 20501849
references.citation: J Immunol. 2000 May 1;164(9):4558-63
references.pmid: 10779757
references.citation: Science. 1996 Mar 1;271(5253):1289-91
references.pmid: 8638112
references.citation: Clin Cancer Res. 2007 Sep 1;13(17):5133-43
references.pmid: 17785568
references.citation: Nat Rev Immunol. 2002 Apr;2(4):227-38
references.pmid: 12001994
references.citation: Immunity. 2002 Dec;17(6):737-47
references.pmid: 12479820
references.citation: J Biol Chem. 2000 May 12;275(19):14307-15
references.pmid: 10799510
references.citation: J Exp Med. 1997 Jul 21;186(2):229-38
references.pmid: 9221752
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1789-96
references.pmid: 18347005
references.citation: Nat Immunol. 2004 Feb;5(2):141-9
references.pmid: 14704792
references.citation: Curr Immunol Rev. 2005 Jan 1;1(1):21-28
references.pmid: 20411047
references.citation: J Clin Oncol. 2003 Jan 1;21(1):135-42
references.pmid: 12506182
references.citation: Nat Rev Cancer. 2005 Apr;5(4):263-74
references.pmid: 15776005
references.citation: Blood. 2005 Apr 1;105(7):2862-8
references.pmid: 15591121
references.citation: J Clin Oncol. 2011 Jun 1;29(16):2273-81
references.pmid: 21263096
references.citation: Proc Natl Acad Sci U S A. 1989 Dec;86(24):10104-7
references.pmid: 2602359
references.citation: J Exp Med. 1996 Apr 1;183(4):1461-72
references.pmid: 8666904
references.citation: Cancer Res. 2001 Dec 15;61(24):8794-802
references.pmid: 11751401
references.citation: Pathobiology. 2008;75(3):200-8
references.pmid: 18550918
references.citation: Annu Rev Immunol. 1999;17:399-433
references.pmid: 10358764
references.citation: Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17134-9
references.pmid: 19805094
references.citation: J Exp Med. 2003 May 5;197(9):1153-63
references.pmid: 12732657
references.citation: J Exp Med. 1999 Dec 6;190(11):1669-78
references.pmid: 10587357
references.citation: Nat Med. 2007 Sep;13(9):1050-9
references.pmid: 17704786
references.citation: Adv Exp Med Biol. 1998;451:159-65
references.pmid: 10026867
references.citation: Annu Rev Immunol. 1996;14:233-58
references.pmid: 8717514
references.citation: Immunity. 1998 Jul;9(1):59-70
references.pmid: 9697836
references.citation: Cancer Cell. 2010 Aug 9;18(2):160-70
references.pmid: 20708157
references.citation: Cancer Res. 2008 Sep 15;68(18):7530-40
references.pmid: 18794141
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7
references.pmid: 21482773
references.citation: Immunity. 1998 Jul;9(1):71-9
references.pmid: 9697837
references.citation: J Natl Cancer Inst. 1988 Sep 7;80(13):1039-44
references.pmid: 3411618
references.citation: J Exp Med. 2003 Aug 18;198(4):569-80
references.pmid: 12925674
references.citation: Chin Med J (Engl). 1994 Sep;107(9):653-7
references.pmid: 7805455
references.citation: Blood. 2010 Apr 8;115(14):2864-71
references.pmid: 20139095
references.citation: Ann N Y Acad Sci. 1993 Aug 12;690:34-41
references.pmid: 8368749
references.citation: Blood. 2009 Jul 16;114(3):589-95
references.pmid: 19349616
references.citation: Nat Rev Clin Oncol. 2011 Jun;8(6):325-32
references.pmid: 21502993
references.citation: Cancer Res. 2001 Sep 15;61(18):6860-7
references.pmid: 11559562
references.citation: Am J Pathol. 2000 Apr;156(4):1133-8
references.pmid: 10751336
references.citation: Cancer Res. 2004 Jun 15;64(12):4328-37
references.pmid: 15205348
references.citation: Science. 2004 May 28;304(5675):1314-7
references.pmid: 15166378
references.citation: Eur J Immunol. 2004 Feb;34(2):336-44
references.pmid: 14768038
references.citation: Immunity. 1998 Jan;8(1):21-30
references.pmid: 9462508
references.citation: Cell Mol Immunol. 2011 Jul;8(4):289-95
references.pmid: 21423201
references.citation: Science. 1999 Dec 10;286(5447):2098-102
references.pmid: 10617422
references.citation: Annu Rev Immunol. 1988;6:465-83
references.pmid: 3289573
references.citation: J Immunother. 2001 Jul-Aug;24(4):363-73
references.pmid: 11565838
references.citation: Cancer Immunol Immunother. 2007 Nov;56(11):1701-10
references.pmid: 17415565
references.citation: J Clin Oncol. 2005 Dec 10;23(35):8950-8
references.pmid: 16061910
references.citation: Cancer Cell. 2010 Nov 16;18(5):485-98
references.pmid: 21035406
references.citation: J Exp Med. 1999 Jan 18;189(2):403-12
references.pmid: 9892622
references.citation: J Immunol. 2005 Jun 15;174(12):7516-23
references.pmid: 15944250